Intech Investment Management LLC increased its position in shares of Danaher Co. (NYSE:DHR - Free Report) by 33.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,938 shares of the conglomerate's stock after acquiring an additional 2,483 shares during the quarter. Intech Investment Management LLC's holdings in Danaher were worth $2,281,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of DHR. FMR LLC grew its holdings in shares of Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate's stock valued at $6,566,116,000 after buying an additional 3,217,631 shares during the period. Bank of New York Mellon Corp lifted its holdings in Danaher by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate's stock worth $1,971,609,000 after acquiring an additional 441,012 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Danaher by 3.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate's stock valued at $1,417,342,000 after acquiring an additional 148,251 shares during the period. Fisher Asset Management LLC increased its holdings in shares of Danaher by 0.6% in the fourth quarter. Fisher Asset Management LLC now owns 4,578,945 shares of the conglomerate's stock worth $1,051,097,000 after acquiring an additional 26,305 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Danaher by 3.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,066,755 shares of the conglomerate's stock worth $933,524,000 after purchasing an additional 135,047 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.
Wall Street Analysts Forecast Growth
DHR has been the subject of a number of research reports. Scotiabank began coverage on Danaher in a research note on Monday, December 23rd. They set a "sector perform" rating and a $265.00 target price for the company. Raymond James reissued a "market perform" rating on shares of Danaher in a research report on Monday, February 3rd. Barclays cut their price objective on shares of Danaher from $275.00 to $240.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 30th. JPMorgan Chase & Co. lowered their target price on Danaher from $310.00 to $300.00 and set an "overweight" rating for the company in a report on Tuesday, January 28th. Finally, StockNews.com lowered Danaher from a "buy" rating to a "hold" rating in a report on Saturday, December 14th. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $278.24.
Read Our Latest Report on Danaher
Insider Transactions at Danaher
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the firm's stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 11.10% of the company's stock.
Danaher Stock Performance
NYSE:DHR traded down $0.44 on Tuesday, hitting $212.36. The company's stock had a trading volume of 3,077,187 shares, compared to its average volume of 3,016,116. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Co. has a one year low of $196.80 and a one year high of $281.70. The stock has a fifty day moving average of $216.92 and a two-hundred day moving average of $238.13. The firm has a market capitalization of $151.78 billion, a P/E ratio of 40.22, a price-to-earnings-growth ratio of 2.66 and a beta of 0.82.
Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the previous year, the firm earned $2.09 earnings per share. Research analysts predict that Danaher Co. will post 7.63 earnings per share for the current year.
Danaher Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date is Friday, March 28th. This is a positive change from Danaher's previous quarterly dividend of $0.27. Danaher's dividend payout ratio is presently 24.24%.
Danaher Company Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
